Chronic Fibrotic Diseases

We are conducting a study seeking healthy males or females, between the ages of 18 to 55 years old who must be non-smokers and must not have a history of alcohol or drug abuse.
The drug will be delivered orally.
We are aiming to evaluate the dose proportionality of the BLD-0409-102 tablet formulation.

This study includes a screening appointment (over 2 days), a treatment period of 8 to 11 days and a follow-up appointment which is 7 days after the last dosing.


Please note that this trial has now closed – if you have any further questions, please call 1800 727 874.